Lidman: Intends to acquire up to 70% of the shares of Beijing Xiansheng Xiangrui Biopharmaceutical Co., Ltd. in cash.

Ledman announcement, the company is planning to acquire a total of no more than 70% of the shares held by the shareholders of Beijing SenseTime Bio-products Co., Ltd. through cash payment. The funds for the transaction will be sourced from the company's own funds and combined with bank mergers and acquisitions loans. Before the transaction, the company did not hold any shares of the target company; after the transaction is completed, the company will acquire control of the target company, which will become a subsidiary of the company. According to preliminary estimates, this transaction is expected to constitute a major asset restructuring as stipulated in the "Management Measures for Major Asset Restructuring of Listed Companies." This transaction does not involve the issuance of shares by the listed company, does not constitute a related party transaction, and will not result in a change in the company's control.